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Abstract
Members of the tumor necrosis factor (TNF) family play key roles in the regulation of in¯ammation,
immune responses and tissue homeostasis. Here we describe the identi®cation of the chicken
homologue of mammalian B cell activating factor of the TNF family (BAFF/BLyS). By searching a
chicken EST database we identi®ed two overlapping cDNA clones that code for the entire open
reading frame of chicken BAFF (chBAFF), which contains a predicted transmembrane domain and
a putative furin protease cleavage site like its mammalian counterparts. The amino acid identity
between soluble chicken and human BAFF is 76%, considerably higher than for most other known
cytokines. The chBAFF gene is most strongly expressed in the bursa of Fabricius. Soluble
recombinant chBAFF produced by human 293T cells interacted with the mammalian cell-surface
receptors TACI, BCMA and BAFF-R. It bound to chicken B cells, but not to other lymphocytes, and
it promoted the survival of splenic chicken B cells in culture. Furthermore, bacterially expressed
chBAFF induced the selective expansion of B cells in the spleen and cecal tonsils when
administered to young chicks. Our results suggest that like its mammalian counterpart, chBAFF
plays an important role in survival and/or proliferation of chicken B cells.
Introduction
Members of the tumor necrosis factor (TNF) family and their
receptors are important regulators of the immune system
[reviewed in (1)]. B cell activating factor of the TNF family
(BAFF, also known as BLyS, TALL-1, THANK, zTNF4 or
TNFSF13b) (2±5) is a new member of the TNF family of
cytokines that plays a major role in B cell survival, proliferation
and differentiation (6). Ligands of the TNF superfamily are type
II single transmembrane proteins that form biologically active
trimers (7). The TNF family de®ning amino acids are located in
the C-terminal extracellular receptor-binding domain of the
uncleaved precursor. BAFF has 33% amino acid identity to
APRIL (a proliferating inducing ligand) and ~20% to TNF-a (2).
The C-terminal extracellular domain can be cleaved by a furin-
like protease resulting in release of the biologically active
soluble cytokine (2). BAFF is produced by macrophages,
dendritic cells and some T cells (2,3,8).
BAFF can bind three receptors of the TNF receptor family,
TACI (transmembrane activator, calcium modulator and
cyclophilin ligand interactor), BCMA (B cell maturation anti-
gen) and BAFF-R (BAFF receptor). Interestingly, BCMA and
TACI also serve as receptors for APRIL (9±12). TACI is
expressed on B cells and activated T cells, whereas BAFF-R
and BCMA are expressed mainly or exclusively on B cells (13±
16). Recent data suggest that BAFF-R may be the primary
receptor responsible for BAFF-mediated function (13). BAFF
promotes B cell survival (17) and, together with signals from
the BCR, BAFF also leads to proliferation of B lymphocytes
(2±5). Treatment of mice with recombinant BAFF increased the
B cell frequency in the spleen and elevated the serum Ig levels
(3,18). The same effects were seen in BAFF transgenic mice
(12,19,20). In addition these mice showed signs of auto-
immune diseases such as systemic lupus erythematosus
(SLE) and, at a later stage, SjoÈgren's syndrome (SS) (12,19±
21), suggesting that BAFF is a key player in human
autoimmune disease. Indeed, some SLE and SS patients
have increased levels of BAFF in the serum (21±23), and BAFF
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null mice display dramatically reduced peripheral B cell
numbers and Ig levels (24,25). Treatment of animals with a
decoy receptor for BAFF reduced the mature B cell pool and
prevented disease in mouse models of SLE and collagen-
induced arthritis (12,26±28).
Little information is available on TNF family members in the
chicken. The coding sequences of the chicken homologues of
CD40 ligand (GenBank accession no. AJ243435), TRAIL
(TNF-related apoptosis inducing ligand; GenBank accession
no. AY057941) and Fas (GenBank accession no. AF296874)
have been reported. Fragments of other putative family
members can be found in EST databases, but their identity
remains questionable. Here we report the cDNA cloning and
biological characterization of the chicken homologue of
mammalian BAFF, designated chBAFF.
Methods
Animals
H.B19 (B19/B19 haplotype) chickens were raised at the Institute
of Animal Physiology, University of Munich. Fertilized eggs of
M11 (B2/B2 haplotype) chickens were obtained from the
Institute for Animal Science, Mariensee (29) and hatched at
the Institute of Animal Physiology, Munich. M11 birds were
used for the experiments described in Fig. 6(B and C).
Cells
Human embryonic kidney 293T cells were maintained in
DMEM supplemented with 10% FBS. Chicken splenocytes,
cells of the bursa of Fabricius, the cecal tonsils and the thymus
were separated by density centrifugation on Ficoll-Paque
(Amersham Pharmacia Biotech, Freiburg, Germany). Peri-
pheral blood lymphocytes were prepared by slow speed
centrifugation as previously described (30). Cells were main-
tained in RPMI 1640 medium with Glutamax (Gibco, Paisley,
UK) supplemented with 10% FCS at 40°C in a CO2 incubator.
Cloning of chBAFF cDNA
The overlapping bursal EST database clones dkfz426_2f7r1
and riken1_33a18r1 (sequence data available at http://
swallow.gsf.de/dt40Est.html) contained the sequence infor-
mation of the 3¢ and 5¢ portion of the chBAFF cDNA
respectively. PCR with the oligonucleotides 5¢-AGCAACGA-
GTAACATGGATTGCAC-3¢ and 5¢-GCTTCAGAGGAGTCTAA-
CTGCAC-3¢ using a 855-23 T cell cDNA library as template
(31) resulted in the ampli®cation of the complete open reading
frame of chBAFF. The PCR product was cloned into pcDNA3.1
(Invitrogen, Karlsruhe, Germany). The sequence has been
assigned the GenBank accession no. AF506010.
RNA isolation and northern blot analysis
RNA was derived from various organs of 3-week-old chickens
using TRIzol reagent (Gibco, Karlsruhe, Germany) according
to the manufacturer's protocol. RNA samples (15 mg per lane)
were size-fractionated by electrophoresis through agarose
gels containing 4% formaldehyde using standard procedures
before blotting onto nylon membranes and hybridization with
the indicated cDNA probes that were radiolabeled with 32P.
Expression of recombinant chBAFF
For expression of chBAFF in eukaryotic cells, PCR was
performed on cDNA of the chicken T cell line 855-23 (31)
with primers 5¢-CAAATGCATTCTATTGTCAACGCAGAAGAA-
AC-3¢ and 5¢-CCGGAATTCTCAGAGGAGTCTAACTGCAC-3¢
that introduced unique NsiI and EcoRI restriction sites near the
ends of the fragment. The resulting PCR product was digested
with NsiI and EcoRI, and ligated behind the hemagglutinin
signal peptide and Flag sequence of a modi®ed PCR-3 vector
(2). 293T cells were transfected with the resulting construct
encoding the 152 C-terminal amino acids of chBAFF or with
empty vector using Metafectene (Biontex, Munich, Germany)
according to the manufacturer's protocol. At 72 h post-
transfection, the supernatants were harvested and cleared of
cell debris by centrifugation. For expression in Escherichia
coli, PCR was performed with primers 5¢-
CGCGGATCCTCTATTGTCAACGCAGAAGAAACA-3¢ and 5¢-
CCCAAGCTTTCAGAGGAGTCTAACTGCACC-3¢ that intro-
duced unique BamHI and HindIII restriction sites. The result-
ing DNA product was cloned between the BamHI and HindIII
restriction sites of the prokaryotic expression vector pQE9
(Qiagen, Hilden, Germany). Expression of this construct in E.
coli strain M15 yielded His-chBAFF with an N-terminal exten-
sion consisting of the peptide Met-Arg-Gly-Ser-(His)6-Gly-Ser.
His-chBAFF was puri®ed by af®nity chromatography on a
nickel chelate agarose column. Puri®cation conditions were
essentially as described previously for chicken IFN-g (31).
Induction was at OD600 = 0.5 for a period of 1 h using an
isopropylthiogalactose concentration of 1.5 mM.
Co-immunoprecipitation and western blotting
To detect the interaction between BAFF and various TNF
receptors, 293T cells were transfected with eukaryotic expres-
sion plasmids for either Flag-chBAFF, Flag-huBAFF (2), Flag-
huEDA1, huBCMA:Fc, muBCMA:Fc, huTACI:Fc, muTACI:Fc
or huBAFFR:Fc (13,32). Cell culture supernatants were
collected at 72 h post-transfection. Samples of the various
receptor:Fc fusion proteins (~500 ng) were mixed with Flag
ligands (200 ng), adjusted to 1 ml with PBS and incubated for
2 h at 4°C on a wheel with 5 ml of Protein A±Sepharose
(Amersham Pharmacia Biotech, Freiburg, Germany). Beads
were harvested, loaded in empty mini-columns, washed 3
times with 200 ml of PBS, eluted with 15 ml of 0.1 M citrate
NaOH, pH 2.7, neutralized and analyzed by western blotting
with anti-Flag M2 antibody (Sigma, Taufkirchen, Germany).
Membranes were subsequently reprobed with horseradish
peroxidase-coupled goat anti-human IgG antibodies.
Receptor±ligand interaction ELISA
Recombinant receptor:Fc fusion proteins and Flag-tagged
soluble ligands were produced in 293T cells as described
above. Speci®c receptor±ligand interactions were detected by
ELISA as described (13). Brie¯y, plates were coated with
mouse anti-human IgG. Plates were then incubated sequen-
tially with receptor:Fc, Flag ligands, biotinylated anti-Flag M2
mAb, horseradish peroxidase-coupled streptavidin and
o-phenylenediamine. To ascertain the functionality of the
recombinant receptors when no speci®c ligand was available,
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100 ml of horseradish peroxidase-coupled rabbit anti-human
IgG (1:4000) was used to demonstrate coating of receptor:Fc.
In vitro survival assay
Cells were cultured in standard RPMI 1640 medium with
Glutamax supplemented with 10% FCS at 5 3 106 cells/well in
24-well plates at 40°C. Supernatants of 293T cells transfected
with either the Flag-chBAFF expression construct or with
empty vector were added to the culture medium at a ®nal
concentration of 5% or at the indicated concentrations for
dose±response experiments. Mammalian BAFF was used at 2
mg/ml, a concentration previously shown to induce maximal B
cell responses in the murine system (17). Absolute numbers of
viable cells in the cultures were determined by Trypan blue
exclusion and the frequency of living B cells [L chain+/
propidium iodide (PI)±] was then analyzed by ¯ow cytometry
as described below. The number of viable B cells was
eventually calculated from these data. To investigate whether
chicken BAFF induces proliferation of B-lymphocytes, puri®ed
splenocytes were resuspended in PBS containing 2% chicken
serum and 2.5 mmol/l carboxy-¯uorescein diacetate succini-
midyl ester (CFSE) stock solution was prepared as described
by the manufacturer (Molecular Probes, Leiden, The
Netherlands) and incubated at 37°C for 30 min in a shaking
water bath. Labeled cells were washed twice in warm RPMI
1640, adjusted to a ®nal concentration of 13107 cells/ml and
cultured in the presence or absence of chBAFF as described
above. As a control, cells were stimulated with 10 mg/ml of
concanavalin A (ConA). After 48 h cells were stained with
antibody AV-20 speci®c for the BU-1 antigen (Southern
Biotechnology Associates, Birmingham, AL) and goat anti-
mouse-PE (Southern Biotechnology Associates). Dead cells
were stained with 7-amino-actinomycin D (7-AAD, Sigma) at
25 mg/ml, and FACS analysis was performed on the living cell
population. Splenic B cell preparations of >93% purity were
obtained by magnetic cell sorting on MACS separation
columns LS (Miltenyi Biotec, Bergisch Gladbach, Germany)
using a chicken Ig light chain (L chain)-speci®c antibody
(Southern Biotechnology Associates, Birmingham, AL), anti-
mouse Ig±FITC (Sigma) and anti-FITC Micro Beads (Miltenyi
Biotec).
In vivo activity of chBAFF
Young chicks (3 days old) were given i.p. injections of either
puri®ed recombinant His-chBAFF or His-MxA (2 mg protein/kg
body mass twice a day) over a period of 7 days. Spleens were
removed and the spleen/body weight index was calculated.
Lymphocytes from the spleen and cecal tonsils were separ-
ated on Ficoll (Amersham Pharmacia Biotech), and subjected
to analysis by ¯ow cytometry. In order to obtain suf®cient
numbers of cecal tonsil lymphocytes, organs from all birds in
each group were pooled prior to lymphocyte isolation.
Flow cytometry
Staining of the cells for ¯ow cytometric analysis was performed
according to standard procedures. Cells were stained with a
mAb against IgM (M1) (33), L chain (Southern Biotechnology
Associates, Birmingham, AL), Bu-1b (34), CD3 (CT3) (35),
CD4 (36), CD8 (37) and TCR2 (38) followed by an anti-mouse
Ig±FITC conjugate (Sigma). Staining with 293T supernatants
transfected with either an expression construct for Flag-
chBAFF or empty vector (dilution 1:10) was followed by
staining with anti-Flag mAb (M2) (Sigma) and anti-mouse Ig±
phycoerythrin (PE) conjugate (Southern Biotechnology
Associates, Birmingham, AL). For two-color immuno¯uores-
cence staining, cells were ®rst incubated with the CD3 or Bu-
1b antibodies followed by anti-mouse Ig±FITC and normal
mouse serum. The cells were subsequently stained with Flag-
chBAFF, Flag-huBAFF or Flag-muBAFF followed by an anti-
Flag±biotin conjugate (Sigma) and streptavidin±PE (Southern
Fig. 1. Comparison of BAFF protein sequences from chicken, man and mouse. Sequences of chBAFF (GenBank accession no. AF506010),
huBAFF (GenBank accession no. AF116456) and muBAFF (GenBank accession no. AF119383) were aligned using the CLUSTAL method.
Amino acid residues are represented by the one-letter code, with columns indicating identical amino acids. Dots indicate residues showing
similarity, de®ned as acidic (D or E), basic (H, K or R), hydrophobic (A, F, I, L, M, P, V or W) or polar (C, G, N, Q, S, T or Y). The TMD is
shaded and the furin cleavage site is boxed.
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Biotechnology Associates). Dead cell discrimination for in vitro
survival assays was done through staining with PI (2.5 mg/ml).
Analysis was performed with a FACScan (Becton Dickinson,
Heidelberg, Germany) using CellQuest software.
Results
Identi®cation of a cDNA for chBAFF
Analysis of a chicken bursal EST database (http://swal-
low.gsf.de/dt40Est.html) indicated that clone dkfz426_2f7r1
and clone riken1_33a18r1 contained sequence information of
a polypeptide with high similarity to human and murine BAFF.
A cDNA encoding the complete protein was obtained by
combining the sequence information of the two overlapping
EST clones (Fig. 1). chBAFF comprises 271 amino acids,
contains a predicted transmembrane domain (TMD) and also
a putative furin protease cleavage site like its mammalian
counterparts. Sequence identity at the amino acid level
between the soluble parts of chBAFF (starting with a serine
residue at position 136) and human or murine BAFF was 76
and 70% respectively.
The expression pro®le of chBAFF was assessed by northern
blot analysis of RNA from various chicken tissues and of the
chicken T cell line 855-23 (31) using a radiolabeled PCR
fragment derived from the chBAFF sequence. This cytokine
seemed to be encoded by an mRNA of ~3 kb length that was
mainly found in the bursa of Fabricius. The transcript was also
present in cells of the 855-23 T cell line (Fig. 2).
Recombinant chBAFF binds to mammalian BAFF-R
Three different receptors of the TNF receptor family, i.e. TACI,
BCMA and BAFF-R, can bind mammalian BAFF. The chicken
homologues of these receptors have not been identi®ed to
date. Therefore, by co-immunoprecipitation analysis we tested
whether chBAFF would bind to the mammalian BAFF-R. To
generate an appropriate chBAFF expression construct, we
Fig. 2. chBAFF gene expression pro®le. (A) chBAFF cDNA was
used to probe a northern blot containing RNA from various chicken
tissues and of the chicken T cell line 855-23 (31). (B) Re-probing of
the membrane was performed with chicken GAPDH cDNA (41) to
estimate the relative amounts of RNA loaded in each lane. The gel
positions of the 28S rRNA and 18S rRNA are indicated.
Fig. 3. chBAFF binds mammalian BAFF-R. The receptor:Fc fusion
proteins huTACI:Fc, muTACI:Fc, huBCMA:Fc, muBCMA:Fc, huBAFF-
R:Fc and huEDAR:Fc were mixed with supernatants of 293T cells
transfected with expression plasmids encoding either Flag-huBAFF,
Flag-chBAFF or Flag-huEDA, precipitated with Protein A±Sepharose
and detected by western blotting using anti-Flag mAb M2 (bottom
panel). The presence of receptor:Fc proteins was visualized with
antibodies to human IgG (top panel). IP: immunoprecipitation; WB:
western blot.
Fig. 4. chBAFF is a ligand for the mammalian receptors TACI,
BCMA and BAFF-R. Binding of Flag-chBAFF and Flag-huBAFF to
various TNF family receptor:Fc fusion proteins was assessed by
ELISA. The plates were coated with the indicated receptor:Fc fusion
proteins, ligand was added and binding was revealed using anti-
Flag M2 mAb.
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performed PCR on cDNA from the chicken T cell line 855-23
(31) to amplify a fragment that encoded the putative soluble
form of chBAFF containing all amino acids located down-
stream of the furin cleavage site. To produce a secreted form
of chBAFF, the resulting cDNA fragment was cloned down-
stream of the hemagglutinin signal peptide and the Flag
sequence of a modi®ed version of the PCR-3 vector which
permits ef®cient expression of cDNAs in eukaryotic cells (32).
Supernatants of transfected 293T cells containing either Flag-
chBAFF or Flag-huBAFF were used to perform co-immuno-
precipitations with soluble fusion proteins consisting of the Fc
domain of human IgG1 fused to the N-terminal extracellular
domains of huTACI, muTACI, huBCMA, muBCMA and
huBAFF-R (huTACI:Fc, muTACI:Fc, huBCMA:Fc,
muBCMA:Fc or huBAFFR:Fc) respectively. The receptor:Fc
fusion protein of the human TNF receptor family member
ectodysplasin A receptor (EDAR:Fc) which binds the human
TNF family ligand EDA1 and conditioned medium from 293T
cells transfected with a expression construct for huEDA1
served as controls. Complexes were precipitated with Protein
A±Sepharose beads, and bound proteins were analyzed by
western blotting using antibodies to human IgG (Fig. 3, top)
and a mAb against the Flag epitope (Fig. 3, bottom). chBAFF
strongly interacted with human and murine TACI:Fc, BCMA:Fc
and human BAFF-R:Fc, and did not interact with human
EDAR:Fc (Fig. 3). To further demonstrate the speci®city of
chBAFF, we tested its ability to bind several additional human
and mouse TNF family receptors in a receptor±ligand inter-
action ELISA. chBAFF and huBAFF interacted with human and
mouse TACI, BCMA and BAFF-R, and both proteins did not
bind to the other TNF family receptors that we tested (Fig. 4).
The functionality of the various plate-coated recombinant
receptor:Fc fusion proteins was demonstrated using the
cognate ligands (data not shown). When no speci®c ligand
was available, horseradish peroxidase-coupled rabbit anti-
human IgG was used to demonstrate successful coating of
receptor:Fc (data not shown).
chBAFF-R are expressed exclusively on B cells
Mammalian BAFF-R are expressed mainly on B cells, sug-
gesting that chBAFF-R might also be expressed on B cells of
lymphoid tissues such as bursa of Fabricius, spleen, cecal
tonsils and peripheral blood lymphocytes. Using recombinant
Flag-chBAFF as a probe, we determined receptor expression
by ¯ow cytometry. We found that most cells of the bursa of
Fabricius expressed receptors for chBAFF (Fig. 5A, left). In
contrast, thymocytes mostly did not bind Flag-chBAFF
(Fig. 5A, right), indicating that chBAFF-R are preferentially
expressed on B cells. This conclusion was con®rmed by two-
color immuno¯uorescence staining (Fig. 5B). chBAFF-R
expression was restricted to the Bu-1b+ B cell population in
peripheral blood lymphocytes, spleen cells and cecal tonsils.
ChBAFF-R expression was absent from CD3+ cells.
Since chicken and mammalian BAFF show a high degree of
homology, we also investigated whether mammalian BAFF
binds to chicken lymphocytes. As shown in Fig. 5(C), selective
binding of human and murine BAFF to chicken B cells could be
demonstrated. The staining patterns and the staining inten-
sities were comparable to those observed with chBAFF.
Fig. 5. Binding of chicken and mammalian BAFF to chicken
lymphocytes. Binding of Flag-chBAFF to isolated cells from (A)
bursa of Fabricius or thymus and (B) cecal tonsils, spleen or
peripheral blood lymphocytes from 7-week-old birds was analyzed
by ¯ow cytometry. (C) The ability of ¯agged huBAFF, muBAFF or
chBAFF to recognize binding sites on isolated chicken splenocytes
was compared by ¯ow cytometry.
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chBAFF promotes the survival of splenic B cells
Mammalian BAFF is a potent survival factor for B cells. To test
whether this also holds true for the chicken system, spleno-
cytes were isolated and treated for 72 h with either
recombinant Flag-chBAFF or control 293T cell supernatant.
Analysis with a mAb speci®c for the B cell-surface marker Bu-
1b combined with PI staining revealed that the B cell
frequency in BAFF-treated samples was ~3-fold higher com-
pared to the controls, whereas the frequency of CD3+ T cells
was not affected (Fig. 6A). To further investigate this effect,
splenocytes were cultured in the presence of different
concentrations of chBAFF. After 48 h, the number of viable
B cells was determined. We observed a dose-dependent
response to cytokine treatment. Saturation was reached if the
BAFF-containing supernatant was used at concentrations
>1% (Fig. 6B). To exclude the possibility that secondary
effects in¯uenced the results in our mixed cell preparations,
several experiments were performed using splenic B cells
enriched to > 93% purity. Although cell death occurred rapidly
in all cultures, the absolute numbers of living cells were higher
in Flag-chBAFF-treated cultures compared to control cultures
at 24, 48 and 72 h (Fig. 6C). On average, viable B cell numbers
Fig. 6. chBAFF promotes the survival of splenic B cells in culture. (A) Splenocytes were cultured for 72 h with 5% Flag-chBAFF-containing
medium or with 5% medium of control cells transfected with the empty plasmid and analyzed by ¯ow cytometry. Cells were stained with PI to
determine the percentage of dead cells, and with mAb to the B cell-speci®c marker Bu-1b and the T cell marker CD3. (B) Splenocytes (5 3
106 cells) were treated with different concentrations (10±0.0001%) of Flag-chBAFF-containing medium or with 10% medium of control cells
transfected with the empty plasmid. After 48 h, the number of viable B cells was determined by Trypan blue exclusion and FACS analysis.
Data represent mean 6 SD of three independent experiments. (C) Kinetics of cell survival. Puri®ed splenic B cell preparations (5 3 106 cells,
purity >93%) were cultured for the indicated times in the presence of 5% Flag-chBAFF-containing medium or 5% medium of control cells
transfected with the empty plasmid. Data represent mean 6 SD of three independent experiments. (D) CFSE-labeled splenocytes were
cultured for 48 h in the presence or absence of chBAFF as described in (A) or as positive control with ConA, and analyzed by ¯ow cytometry.
Cells were stained with 7-AAD, and two color FACS analysis was performed on the living cell population.
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were nearly 3-fold higher after 48 h and ~5-fold higher after
72 h, strongly indicating that recombinant chBAFF promoted B
cell survival in these cultures. To de®nitely prove that this effect
was not a consequence of B cell proliferation, we cultured
CFSE-labeled splenocytes with chBAFF or ConA. ConA-
stimulated cultures showed evidence for two to three rounds
of cell division after 48 hours. Under these conditions no cell
proliferation was observed in the chBAFF-treated culture or in
the untreated control, although the number of living B cells
increased from 13.5% to 26.5% in response to chBAFF (Fig.
6D). The almost threefold decrease in the number of living B
cells in the ConA-treated culture can probably be explained
by the strong increase of T cells.
Since human and mouse BAFF ef®ciently bound to chicken
B cells, we next determined whether they are also biologically
active on chicken cells. Splenocytes were treated with ¯agged
human or mouse BAFF (2 mg/ml) for 48 h before the number of
viable B cells was determined. Cells treated with Flag-chBAFF
(5%) or control supernatant (5%) served as positive and
negative controls. We found that the mammalian BAFF
preparations were nearly as potent in preventing premature
death of chicken splenocytes as chBAFF (Table 1).
Increased B cell numbers in chicks treated with
recombinant chBAFF
To determine the in vivo activity of chBAFF, 3-day-old chicks
(seven animals per group) were injected i.p. twice a day for 7
days with 2 mg/kg body weight of E. coli-derived chBAFF (His-
chBAFF) or with the same amount of control protein (His-MxA).
The spleen/body weight index was signi®cantly increased (P <
0.05, in the Wilcoxon test and Student's t-test) in chBAFF-
treated birds (Table 2), indicating an increase of total
lymphocyte numbers in the spleen. Flow cytometric analysis
of spleens and cecal tonsils with various mAb revealed that the
percentage of B cells, but not T cells, was ~2-fold higher in
chBAFF-treated animals as compared to control animals
(Table 3). The Ig light chain (L chain) staining pattern of a
representative pair of chBAFF- and control-treated animals is
shown in Fig. 7. Since splenic lymphocyte numbers and B cell
frequencies were higher in chBAFF-treated animals, it can be
concluded that chBAFF enhances survival or induces select-
ive proliferation of B cells in spleen and cecal tonsils of
cytokine-treated animals.
Discussion
Here we report the identi®cation and biological characteriza-
tion of the chicken homologue of mammalian BAFF. By
analyzing the BLAST search results of two chicken EST
databases, we identi®ed overlapping cDNA clones that code
for the complete open reading frame of chBAFF. Like its
mammalian counterparts, chBAFF exhibits a type II trans-
membrane protein organization. Mammalian BAFF is pro-
cessed by a furin-like protease after a characteristic sequence
motif which results in the release of biologically active soluble
protein (2). chBAFF contains a putative furin cleavage site at
the corresponding position, indicating that it might be
Table 1. Effect of human and murine BAFF on chicken
splenocytes in vitro
No. of viable B cells (3105) Mean 6 SD
1 2 3
huBAFF 0.91 1.90 1.72 1.51 6 0.4
muBAFF 1.39 1.59 2.10 1.69 6 0.3
chBAFF 1.46 2.28 2.04 1.93 6 0.4
Control 0.26 0.76 0.92 0.65 6 0.3
Splenocytes were cultured for 48 h at 5 3 106 cells per well in
24-well plates with either Flag-chBAFF (5%), control supernatant
(5%), Flag-huBAFF (2 mg/ml) or Flag-muBAFF (2 mg/ml). Three
independent experiments were performed.
Table 2. chBAFF-dependent increase in spleen weight
Spleen weight
(mg)
Body weight
(g)
Spleen/body
weight index
(mg/g)a
chBAFF 76.8 6 24.0 64.2 6 2.1 1.2 6 0.3
control 55.3 6 22.8 66.5 6 11.9 0.8 6 0.2
Seven animals per group were treated with either chBAFF or control
protein (2 mg/kg body mass twice a day) for 7 days. Spleen and
body weights were determined, and the spleen/body weight index of
each animal was calculated. Mean values 6 SD are given for each
group.
aThese values are signi®cantly different (P < 0.05; Wilcoxon t-test).
Table 3. Selective expansion of the B cell population in spleen and cecal tonsils of chBAFF-treated chicks
Percentage of positive cells
L chain Bu-1b IgM CD3 CD4 CD8 TCR-2
Spleen
chBAFF 42.0 6 7.5 41.5 6 5.0 43.0 6 6.6 51.9 6 6.5 29.0 6 2.3 22.8 6 5.2 33.9 6 3.4
control 20.8 6 7.0 22.6 6 6.0 21.4 6 6.6 64.9 6 6.0 32.1 6 1.8 30.6 6 5.7 41.6 6 4.8
Cecal tonsilsa
chBAFF 38.6 38.5 37.2 54.9 34.8 26.2 35.7
control 15.5 23.5 22.6 67.7 45.9 24.1 48.9
Five animals per group were treated with either chBAFF or control protein (2 mg/kg body mass twice a day) for 7 days. The average
percentages of cells expressing the various surface markers (6 SD) are shown.
aCecal tonsils from animals of each group were pooled prior to lymphocyte isolation.
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processed similarly. The predicted soluble forms of chicken
and mammalian BAFF are surprisingly similar. At the amino
acid level, soluble chBAFF is 70 and 76% identical to mouse
and human BAFF respectively. Most other avian cytokines
show <30% identity to their mammalian counterparts (39).
The high sequence conservation suggested that chBAFF
might bind to mammalian BAFF-R. By performing appropriate
co-immunoprecipitation experiments and by using a receptor±
ligand interaction ELISA we were able to demonstrate that this
was indeed the case. Like human BAFF, chBAFF bound
speci®cally to the mammalian receptors TACI, BCMA and
BAFF-R. The receptors for BAFF in mammals are expressed
on B cells and on some T cells (12±14). Our ¯ow cytometric
analyses revealed that Flag-tagged chBAFF bound a popu-
lation of cells which was abundantly present in chicken spleen,
bursa of Fabricius, peripheral blood lymphocytes and cecal
tonsils, but which was virtually absent in the thymus. Since
~98% of the lymphocytes present in the bursa of Fabricius are
B cells, our data strongly suggested that the receptors for
BAFF in the chicken are expressed predominantly if not
exclusively on B cells, which was con®rmed by two-color
immuno¯uorescence staining.
As expected from the known activity of mammalian BAFF,
chBAFF did not induce B cell proliferation but was clearly able
to prolong the survival of splenic B cells in cell culture.
Mammalian BAFF also bound to chicken B cells and promoted
their survival, indicating functional cross-reactivity between
mammalian and avian BAFF. chBAFF further promoted the
speci®c expansion of the B cell population in the spleen and
cecal tonsils of young chicks that were treated with recombi-
nant cytokine. Further studies are needed to determine
whether the in vivo expansion of B cells resulted from
enhanced survival or from increased proliferation of this
lymphocyte population. In contrast to spleen and cecal tonsils,
the number of B cells in the bursa of Fabricius of treated chicks
was not increased and the size of the organ remained
unchanged. This differential response to chBAFF of B cells
in various lymphoid organs is not really surprising. Indeed,
studies with transgenic and knockout mice have clearly
demonstrated that mammalian BAFF is critical for B cell
maturation in peripheral lymphoid organs, but is not required
for B cell development in the bone marrow, despite the fact
that BAFF mRNA is moderately expressed in this compartment
(3,17,24). In birds, early development of B cells does not take
place in the bone marrow, but in the bursa of Fabricius (40). By
analogy with the mammalian system, the ®rst steps of B cell
development in the chicken are not expected to be dependent
on BAFF. However, in view of the fact that the chBAFF gene is
expressed most strongly in the bursa, it may well be that BAFF
is important for bursal B cell survival. chBAFF could play a role
in a late B cell differentiation step, shortly before the B cells exit
from the bursa. Since administration of exogenous BAFF did
not positively affect the number of B cells in the bursa, at ®rst
glance, this result seems to argue against this view. It is
possible, however, that the level of endogenous BAFF is
already very high in the bursa and that administration of
exogenous BAFF has no additive effect simply because the
BAFF-R on bursal B cells are already saturated with ligands.
In mammals, BAFF is expressed by cells of myeloid origin
and, to a lesser extent, by T cells, but not by B cells (2,3,8).
Since spleen did not contain detectable levels of BAFF
transcripts, mature chicken B cells cannot be the major
producers of BAFF. Thus, most likely, BAFF is synthesized by
either bursa stromal cells or immature B cells. To further
investigate the role of this cytokine in bursal B cell develop-
ment, the activity of endogenous chBAFF needs to be blocked
in vivo. Since the generation of knockout birds is still
impossible, alternative strategies aimed at neutralizing this
cytokine with antagonistic antibodies or with soluble decoy
receptors such as BAFF-R:Fc should be considered. Results
presented here (Figs 3 and 4) strongly indicate that BAFF-R:Fc
has the potential to neutralize the activity of chBAFF.
In summary, by identifying chicken BAFF as well as suitable
decoy receptors we paved the way for new experimental
approaches aimed at a better understanding of B cell
development in the chicken. Furthermore, our work is the
®rst functional characterization of a chicken TNF family
member.
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Fig. 7. Increased B cell numbers in chicks treated with recombinant
chBAFF. Effect of i.p. administration of His-chBAFF or control protein
(His-MxA) on the frequency of various cell types in the spleen and
cecal tonsils of 10-day-old chicks at 7 days post-initiation of
treatment. Cells were stained with the indicated mAb and analyzed
by ¯ow cytometry. A representative data set of spleen and cecal
tonsils from a pair of chBAFF- and control-treated animals stained
for the Ig light chain (L chain) is shown.
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Abbreviations
APRIL a proliferating inducing ligand
BAFF B cell activating factor of the TNF family
BAFF-R BAFF receptor
BCMA B cell maturation antigen
PE phycoerythrin
PI propidium iodide
SS SjoÈgren's syndrome
SLE systemic lupus erythematosus
TACI transmembrane activator, calcium modulator and
cyclophilin ligand interactor
TMD transmembrane domain
TNF tumor necrosis factor
TRAIL TNF-related apoptosis inducing ligand
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